Moreover, 19% of patients treated with maribavir achieved CMV DNA level less than lower limit of quantification and CMV infection symptom control at week 8 and maintained treatment effect through ...

Quantitative detection of CMV DNA has been substituted for the antigenemia assay for the initiation of antiviral treatment in allogeneic stem cell transplant recipients. 14,15,16,18,22 It has been ...

Question. What are the diagnostic criteria for cytomegalovirus (CMV) seropositivity: IgM, IgG, PCR, or leukocytic viral DNA?. Adel Al-Ansary, MD Response from Marc E. Uknis, MD ...

Significant levels of cytomegalovirus (CMV) DNA are common in older African children with perinatally acquired HIV infection, even in children treated with antiretroviral therapy (ART), according ...

Maribavir is an orally bioavailable anti-CMV compound that targets and inhibits the UL97 protein kinase and ... defined as plasma CMV DNA less than 137 IU/mL in 2 consecutive tests separated by ...

Takeda Pharmaceutical TAK announced that the FDA has granted approval to Livtencity (maribavir) for treating post-transplant cytomegalovirus (“CMV”) infection/disease in pediatric patients ...

U.S. health regulators on Thursday approved a first-of-its-kind DNA test by Swiss drugmaker Roche Holding AG to help physicians track progress in treating organ transplant patients for a common virus.

U.S. health regulators approved a first-of-its-kind DNA test by Roche Holding AG to help physicians track progress in treating organ transplant patients for cytomegalovirus infection.